What the Company Does

HUTCHMED operates as a science-driven organization dedicated to developing novel small-molecule oncology drugs. The company's core scientific strength lies in its ability to design and develop highly selective tyrosine kinase inhibitors and other targeted therapies that address unmet medical needs in cancer treatment. Unlike many biotechnology firms that rely on in-licensing external compounds, HUTCHMED has built its pipeline predominantly through internal discovery efforts, developing proprietary molecules from the earliest research stages.

The company's research and development activities are conducted through a large, dedicated team of scientists and clinicians. It maintains substantial in-house capabilities covering medicinal chemistry, biology, pharmacology, clinical development, and regulatory affairs. This vertical integration allows HUTCHMED to control the entire lifecycle of its drug candidates and to pursue global development strategies for its most promising assets.

HUTCHMED conducts clinical trials both within China and internationally, working with regulatory authorities including China's National Medical Products Administration, the U.S. Food and Drug Administration, and the European Medicines Agency. The company has established a significant commercial infrastructure in China, employing a substantial sales and marketing team to promote its approved products to hospitals and physicians across the country.

Approved Products

HUTCHMED has successfully brought several novel drugs to market, which represents a major achievement for a China-based innovative pharmaceutical company. Its key commercialized products include:

Fruquintinib (marketed as Elunate in China and Fruzaqla internationally) is a highly selective inhibitor of vascular endothelial growth factor receptors. It is approved for the treatment of metastatic colorectal cancer. Fruquintinib has achieved regulatory approval in the United States, Europe, and Japan through a partnership with Takeda, marking one of the first China-discovered cancer drugs to gain broad international approval.

Surufatinib (marketed as Sulanda in China) is an angio-immuno kinase inhibitor that targets VEGFR, FGFR, and CSF-1R. It is approved in China for the treatment of advanced neuroendocrine tumors, addressing both pancreatic and extra-pancreatic forms of the disease.

Savolitinib (marketed as Orpathys in China) is a selective MET tyrosine kinase inhibitor developed in collaboration with AstraZeneca. It is approved in China for the treatment of non-small cell lung cancer with MET exon 14 skipping alterations.

Research and Development Pipeline

Beyond its approved products, HUTCHMED maintains an extensive pipeline of drug candidates in various stages of clinical and preclinical development. The company continues to advance its existing marketed drugs into new indications and combination regimens while progressing newer molecules through clinical trials.

The pipeline includes candidates targeting a range of oncology indications, exploring both monotherapy and combination approaches, including combinations with immune checkpoint inhibitors. HUTCHMED also develops therapies aimed at immunological and inflammatory diseases, expanding beyond its oncology roots. The company invests heavily in research to identify next-generation targeted agents that offer improved efficacy and tolerability profiles.

Partnerships and Collaborations

Strategic collaboration is a central element of HUTCHMED's business model. The company has forged partnerships with major global pharmaceutical companies to accelerate the development and commercialization of its assets. Its collaboration with AstraZeneca has supported the development of savolitinib, while its partnership with Takeda enables the global commercialization of fruquintinib outside of China, Hong Kong, and Macau. These alliances provide HUTCHMED with access to global commercial networks, additional research funding, and shared development expertise while allowing the company to retain significant economic interest in its discoveries.

Commercial Operations

HUTCHMED has developed a robust commercial platform within China to market its oncology products. This includes an experienced field force covering major cities and hospitals, medical affairs teams, and market access specialists who work to secure reimbursement and inclusion in China's National Reimbursement Drug List. Gaining reimbursement listing is critical for expanding patient access in the Chinese healthcare market, and HUTCHMED has successfully achieved this for several of its products.

Corporate Position and Significance

HUTCHMED occupies an important position in the evolution of China's pharmaceutical industry, representing the transition from a market historically dominated by generic manufacturing toward genuine innovation and novel drug discovery. The company's ability to discover, develop, and gain international approval for homegrown cancer therapies demonstrates the maturation of China's biotechnology sector and its growing contribution to global medicine.

The company continues to reinvest in its scientific capabilities, expand its clinical footprint, and pursue global registration for its most promising candidates. Through its combination of internal innovation, strategic partnerships, and commercial execution, HUTCHMED aims to deliver meaningful new treatment options to cancer patients in China and around the world.